Comparative Pharmacology
Head-to-head clinical analysis: ANTRENYL versus DETROL LA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANTRENYL versus DETROL LA.
ANTRENYL vs DETROL LA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antrenyl (oxyphenonium bromide) is a quaternary ammonium anticholinergic agent that competitively blocks acetylcholine at muscarinic receptors in smooth muscle, exocrine glands, and the CNS, leading to reduced gastrointestinal motility and secretion.
Tolterodine is a competitive muscarinic receptor antagonist. It blocks acetylcholine binding at muscarinic receptors (M1–M5), reducing detrusor muscle contraction and bladder pressure, thereby increasing bladder capacity and decreasing urinary frequency.
50 mg orally 3 times daily initially, then adjust to 50-100 mg 3 times daily; 20 mg intramuscularly or intravenously every 4-6 hours as needed.
4 mg orally once daily; may be reduced to 2 mg once daily based on tolerability.
None Documented
None Documented
2-4 hours (terminal), requiring q6-8h dosing for sustained anticholinergic effect
Terminal elimination half-life is approximately 7 hours (range 5-10 hours) for the extended-release formulation, allowing once-daily dosing.
Renal (80% as unchanged drug and metabolites), biliary/fecal (20%)
Approximately 77% eliminated in urine (primarily as metabolites, <1% unchanged) and 17% in feces.
Category C
Category C
Anticholinergic
Anticholinergic